DURASEAL XACT, UNKNOWN XXX-DURASEAL XACT

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a consumer report with the FDA on 2019-05-06 for DURASEAL XACT, UNKNOWN XXX-DURASEAL XACT manufactured by Integra Lifesciences Corp.

Event Text Entries

[144179088] The device is not expected to be returned to the manufacturer for evaluation. The plant investigation is in progress and a supplemental medwatch report will be submitted upon completion of the investigation.
Patient Sequence No: 1, Text Type: N, H10


[144179089] A (b)(6) patient reported that she had an unspecified surgery on (b)(6) 2019 in which duraseal was used. She has had multiple magnetic resonance imagings (mris) post surgery and the surgeon has found a "glue mass" that formed inside her body. The patient stated she has spoken with her surgeon multiple times and wanted the duraseal removed but the surgeon would not remove the product. The patient reported that her pain has become worse since the surgery. She was having intense nerve pain on her spinal cord. Additional information was received on 03may2019 with the following: information from operative notes indicated that prior to dural closure, morphine and clonidine were injected into the intrathecal space to assist with pain control. Valsalva maneuver to 40 mmhg was performed to ensure that there was no active cerebrospinal fluid (csf) leak. The dural opening was then covered using duraseal. Hemostasis was again obtained using bipolar cautery as well as floseal packing with a cottonoid. To this point in the operation, there were no neuromonitoring changes. The patient reported that the mass was discovered one and a half weeks after surgery as symptoms progressed and it was seen on mri; the surgeon told the patient? It was just glue?. The patient reported she was 14 weeks post surgery and still had a mass that was tethering her spinal cord to her lamina, making it impossible to stand and walk for any period of time. The patient stated she was told by her surgeon that? A lot? Of duraseal was used and was advised that it would be gone at 12 weeks. The patient reported her pain level being 10 out of 10. She stated that she was watching the mass closely for another two weeks before scheduling a revision surgery. The mass has reduced in size by about one third (1/3) over 14 weeks. It has gone from completely compressing her thecal sack to sitting on it and it? S adhesive properties were making any movement excruciating. She stated that the glue completely displaced her nerves from l4/l5 down.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3003418325-2019-00014
MDR Report Key8583496
Report SourceCONSUMER
Date Received2019-05-06
Date of Report2019-04-10
Date Mfgr Received2019-11-01
Date Added to Maude2019-05-06
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMRS. VIVIAN NELSON
Manufacturer Street311 ENTERPRISE DRIVE
Manufacturer CityPLAINSBORO NJ 08536
Manufacturer CountryUS
Manufacturer Postal08536
Manufacturer Phone6099362319
Manufacturer G1INTEGRA LIFESCIENCES CORP
Manufacturer Street311 ENTERPRISE DRIVE
Manufacturer CityPLAINSBORO NJ 08536
Manufacturer CountryUS
Manufacturer Postal Code08536
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameDURASEAL XACT, UNKNOWN
Generic NameDURASEAL SPINE
Product CodeNQR
Date Received2019-05-06
Catalog NumberXXX-DURASEAL XACT
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerINTEGRA LIFESCIENCES CORP
Manufacturer Address311 ENTERPRISE DRIVE 311 ENTERPRISE DRIVE PLAINSBORO NJ 08536 US 08536


Patients

Patient NumberTreatmentOutcomeDate
10 2019-05-06

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.